MarketCap
Facebook
X
TelegramAnnual report 2025
added 02-26-2026
Amphastar Pharmaceuticals Cash and Cash Equivalents 2011-2026 | AMPH
Annual Cash and Cash Equivalents Amphastar Pharmaceuticals
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 170 M | 152 M | 145 M | 156 M | 127 M | 94.5 M | 73.7 M | 86.3 M | 65.6 M | 72.4 M | 66.1 M | 67.8 M | 53.6 M | 50.2 M | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 170 M | 50.2 M | 98.5 M |
Quarterly Cash and Cash Equivalents Amphastar Pharmaceuticals
| 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 216 M | 188 M | 183 M | 152 M | 192 M | 190 M | 201 M | 144 M | 271 M | 151 M | 177 M | 156 M | 157 M | 166 M | 173 M | 126 M | 107 M | 125 M | 102 M | 94.5 M | 92.6 M | 92.6 M | 92.6 M | 73.7 M | 73.7 M | 73.7 M | 73.7 M | 86.3 M | 86.3 M | 86.3 M | 86.3 M | 65.6 M | 65.6 M | 65.6 M | 65.6 M | 72.4 M | 72.4 M | 72.4 M | 72.4 M | 66.1 M | 66.1 M | 66.1 M | 66.1 M | 67.8 M | 67.8 M | 67.8 M | 67.8 M | 53.6 M | 53.6 M | 53.6 M | - | 50.2 M | - | - | - | 53.7 M | - | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 271 M | 50.2 M | 107 M |
Cash and Cash Equivalents of other stocks in the Biotechnology industry
| Issuer | Cash and Cash Equivalents | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
 |
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M |  Germany |
 |
Amarin Corporation plc
AMRN
|
135 M | $ 14.63 | -0.34 % | $ 6.07 B |  Irlanda |
 |
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M |  USA |
 |
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M |  Canada |
 |
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | USA |
 |
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | USA |
 |
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M |  China |
 |
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B |  France |
 |
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | USA |
 |
Corbus Pharmaceuticals Holdings
CRBP
|
28.5 M | $ 8.71 | 4.81 % | $ 116 M | USA |
 |
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | France |
 |
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | USA |
 |
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M |  Britain |
 |
Cabaletta Bio
CABA
|
83 M | $ 2.77 | -0.54 % | $ 278 M | USA |
 |
Editas Medicine
EDIT
|
147 M | $ 2.31 | -0.43 % | $ 205 M | USA |
 |
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | USA |
 |
Eton Pharmaceuticals
ETON
|
25.9 M | $ 23.54 | -1.26 % | $ 633 M | USA |
 |
AgeX Therapeutics
AGE
|
3.06 M | - | -10.17 % | $ 12.2 K | USA |
 |
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | USA |
 |
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | USA |
 |
Esperion Therapeutics
ESPR
|
168 M | $ 2.82 | 2.18 % | $ 586 M | USA |
 |
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | Canada |
 |
Equillium
EQ
|
30.3 M | $ 2.01 | -2.43 % | $ 115 M | USA |
 |
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | USA |
 |
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | USA |
 |
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | USA |
 |
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M |  Israel |
 |
Halozyme Therapeutics
HALO
|
134 M | $ 63.44 | 0.31 % | $ 7.6 B | USA |
 |
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | USA |
 |
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.33 | -0.38 % | $ 339 M | Britain |
 |
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | USA |
 |
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B |  Cayman-islands |
 |
Harmony Biosciences Holdings
HRMY
|
753 M | $ 27.56 | -0.11 % | $ 1.58 B | USA |
 |
Heron Therapeutics
HRTX
|
28.6 M | $ 0.83 | 3.72 % | $ 138 M | USA |
 |
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | USA |
 |
Immunic
IMUX
|
15.5 M | $ 1.26 | -4.55 % | $ 196 M | USA |
 |
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | USA |
 |
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | USA |
 |
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | USA |
 |
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | USA |
 |
Avid Bioservices
CDMO
|
38.1 M | - | - | $ 789 M | USA |
 |
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | Germany |
 |
Iterum Therapeutics
ITRM
|
24.1 M | $ 0.18 | 2.27 % | $ 3.55 M | Irlanda |
 |
Johnson & Johnson
JNJ
|
19.7 B | $ 240.64 | 0.27 % | $ 579 B | USA |
 |
Kala Pharmaceuticals
KALA
|
51.2 M | $ 0.21 | -0.42 % | $ 797 K | USA |
 |
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | USA |
 |
CRISPR Therapeutics AG
CRSP
|
348 M | $ 47.9 | 1.72 % | $ 4.31 B |  Schweiz |